Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Rare leptin in non-alcoholic fatty liver cirrhosis: A case report
Yao-Bin Nong, Hong-Na Huang, Jing-Jing Huang, Yuan-Qin Du, Wen-Xuan Song, De-Wen Mao, Yue-Xue Zhong, Rong-Huo Zhu, Xi-Yu Xiao, Rui-Xi Zhong
Yao-Bin Nong, Yuan-Qin Du, Wen-Xuan Song, Yue-Xue Zhong, Rong-Huo Zhu, Xi-Yu Xiao, Rui-Xi Zhong, The First Clinical Medical College, Guangxi University of Chinese Medicine, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Hong-Na Huang, Department of Internal Medicine of Traditional Chinese Medicine,The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Jing-Jing Huang, Department of Spleen and Stomach Liver Diseases, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530022, Guangxi Zhuang Autonomous Region, China
De-Wen Mao, Department of Hepatology, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, China
Author contributions: Nong YB and Huang HN contributed equally to this work; Huang JJ, Du YQ, Song WX, Mao DW, Zhong YX, Zhu RH, Xiao XY, Zhong RX designed the research study; Nong YB performed the research; Nong YB and Huang HN analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.
Supported by Guangxi Provincial Natural Science Foundation of China, No. 2022GXNSFBA035485 and No. 2022GXNSFAA035460; Basic Ability Improvement Project of Young and Middle-aged Teachers in Guangxi Colleges and Universities, No. 2019KY0313; the National Natural Science Foundation of China, No. 81760845 and No. 81403382; and Innovation Project of Guangxi Graduate Education, No. YCSW2021220 and No. YCXJ2021056.
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: The authors have nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Jing-Jing Huang, Doctor, Chief Doctor, Department of Spleen and Stomach Liver Diseases, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 327 Xianhu Dadao, Qingxiu District, Nanning 530022, Guangxi Zhuang Autonomous Region, China.
55869563@qq.com
Received: May 19, 2022
Peer-review started: May 19, 2022
First decision: July 12, 2022
Revised: July 27, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: October 6, 2022
Processing time: 130 Days and 18.9 Hours
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD)-related cirrhosis is mainly caused by NAFLD by causing inflammation which leads to fibrosis. The role of leptin in NAFLD-related cirrhosis has been rarely reported.
CASE SUMMARY
This study presents the case of a 65-year-old male patient who was referred to The First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi, China, for diagnosis and treatment for liver cirrhosis. Initially, the cause of liver cirrhosis was unknown. After radiology, laboratory examination, pathological results and analysis of the patient’s signs and symptoms, the case was finally diagnosed with final NAFLD-related cirrhosis. Although this study reports a single case, the findings might expand the understanding of leptin’s role in NAFLD-related cirrhosis and might provide a basis for the clinical diagnostic criteria, pathological features and treatment of NAFLD-related cirrhosis.
CONCLUSION
Although the occurrence of marasmus NAFLD-related cirrhosis is rare, it needs to be distinguished from other liver diseases, including viral hepatitis, drug-induced liver disease, Wilson's disease and autoimmune liver disease. Aggressive treatment is needed to prevent the progression of NAFLD-related cirrhosis.
Core Tip: The patients with marasmus might also develop non-alcoholic fatty liver disease cirrhosis and it needs to be distinguished from other liver diseases, including viral hepatitis and drug-induced liver disease. Early liver biopsy histopathology and the liver fibrosis scoring system are important methods for the diagnosis of liver cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. Aggressive treatment is needed to prevent the progression of NAFLD-related cirrhosis, thereby requiring immediate clinical attention.
